Lung imaging software developer Vida Diagnostics has raised another $2 million in financing intended to help the company develop and commercialize its software.
Vida received the funds from OSF Ventures, the corporate investment arm of OSF HealthCare. The funding complements $11 million that Vida received in February, bringing the total value of the funding round to $13 million.
Vida has developed LungPrint, a software platform to help radiologists and pulmonologists manage patients with respiratory disease. The software has applications in chronic obstructive pulmonary disorder (COPD), lung cancer, and other pulmonary diseases, and Vida believes it can also play a role in managing new populations that are experiencing COVID-19.
